National Liver Cancer Screening Trial
Recruiting · Phase 4 · NCT06084234
Conditions: Carcinoma, Hepatocellular, Liver Cancer, Liver Cirrhosis, Hepatitis B
At a glance
- Research payments reported, 2025
- $500,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 5,500
About the trial
- Sponsor
- University of Texas Southwestern Medical Center (with National Cancer Institute (NCI), University of Pennsylvania, University of Michigan, Dana-Farber Cancer Institute, Baylor College of Medicine, Fred Hutchinson Cancer Center, The Cleveland Clinic)
- Tested
- GALAD (diagnostic_test), Liver Ultrasound with or without AFP (diagnostic_test)
- Dates
- Started 2023-12-26; completion 2034-12-31
- Results posted
- Not yet
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), and HCC etiology (viral vs. non-viral). Patients will be recruited from 15 sites (mix of tertiary care and large community health systems) over a 3-year period, and the primary endpoint of the phase …
From ClinicalTrials.gov, last updated 2026-09-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Fujifilm Healthcare Americas Corporation reported $500,000 in research payments for this study in 2025 (1 payments).
Products named: Utaswako Afp-L3
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Texas Southwestern $500,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.